<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433067</url>
  </required_header>
  <id_info>
    <org_study_id>UFranche-Comte</org_study_id>
    <nct_id>NCT02433067</nct_id>
  </id_info>
  <brief_title>Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer</brief_title>
  <acronym>CARDAPAC</acronym>
  <official_title>Impact of Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer, During Treatment With Trastuzumab in Adjuvant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fabienne Mougin-Guillaume</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Franche-Comté</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to examine the effects of 3 months of physical activity intervention
      on myocardial function (Left ventricular ejection fraction) in patients with HER2+ breast
      cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: To evaluate in patients with HER2 + breast cancer, treated only by
      trastuzumab, the impact of three months individualized physical activity intervention (45
      minutes, 3 times per week) on left ventricular ejection fraction (LVEF).

      Secondary objectives: To evaluate the impact of physical activity intervention on body
      composition, muscle function, metabolic, hormonal and inflammatory responses, pain, fatigue
      and quality of life.

      This study examines patients aged 18 to 65 years, diagnosed with early breast cancer with
      HER2 overexpression confirmed histologically and eligible to receive treatment with
      trastuzumab (adjuvant).

      This study includes 3 assessments phases: baseline (T0), 3 months (T3) and 6 months (T6) for
      both arms.

      The programme is organised as follows: Arm A &quot;standard oncologic care coupled with physical
      activity intervention (3 times / week) &quot; for 3 months ; Arm B (control group) &quot;standard
      oncologic care&quot;.

      Between T3 and T6, volontary physical activity level will follow by actimetry.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>The Left Ventricular Ejection Fraction (LVEF) will be evaluated baseline (T0), and 6 months (T6), to see if there is a significant change</time_frame>
    <description>evaluated with echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight and volume of left and right ventricular</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated byimpedance and with tape measure and pliers of Harpenden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic responses</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal voluntary quadriceps</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with chair quadriceps with strain gauge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of physical activity</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function (at rest and during exercise)</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with respiratory functional test and maximal exercise test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hormonal responses</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory responses</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Physical activity intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Arm A &quot;standard oncologic care coupled with physical activity intervention (3 times / week) &quot; during 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>- Arm B (control group) &quot;standard oncologic care&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical activity intervention</intervention_name>
    <description>Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.</description>
    <arm_group_label>Physical activity intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>standard oncologic care</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 to 65 years

          -  First breast cancer HER2 + histologically confirmed,

          -  WHO grade Performance Index ≤1

          -  Normal renal function (creatinine clearance ≥ 60 ml min-1)

          -  Normal heart function with LVEF ≥ 50%

          -  Normal liver function (AST and ALT normal)

          -  Physical activity certificate issued by a cardiologist or an oncologist,

          -  Active contraception or postmenopausal

        Exclusion Criteria:

          -  Patients aged under 18 and over 65

          -  Patients having no breast cancer HER2+

          -  Patients with metastases

          -  Heart failure (LVEF ≤50%) and respiratory (O2 saturation ≤ 92%),

          -  Autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis)

          -  Symptomatic osteoarthritis,

          -  Cardiovascular diseases (angina or uncontrolled high blood pressure) or heart-lung
             (chronic obstructive pulmonary disease)

          -  Patients suffering from malnutrition (Body Mass Index (BMI) &lt;18 kg m-2) or weight loss
             of over 10% during the last 3 months,

          -  Patients with psychiatric or cognitive disorders deemed unsuitable for a sporting
             activity

          -  Pregnant or lactating Patients.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Meneveau</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabienne Mougin-Guillaume, Ph.D</last_name>
    <email>fabienne.mougin-guillaume@univ-fcomte.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Besancon</city>
        <state>Doubs</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabienne Mougin-Guillaume, Ph.D</last_name>
      <email>fabienne.mougin-guillaume@univ-fcomte.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Franche-Comté</investigator_affiliation>
    <investigator_full_name>Fabienne Mougin-Guillaume</investigator_full_name>
    <investigator_title>Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

